Program and Agenda, Roundtable on Prizes

Written by James Love
Wednesday, 07 January 2009

 Program and Agenda

(Draft 7Jan09)

Roundtable on De-linking R&D Incentives from Prices

Designing Innovation Inducement Prizes for Diagnostics, New Drugs and Vaccines for Type II and III diseases and conditions, with a particular focus on TB and Chagas Disease

 

DATE: January 16-17, 2009 (Weekend before the WHO Executive Board)

LOCATION: Geneva, Switzerland – MSF Office – Rue de Lausanne, 78

Co-Sponsors: KEI, HAI, MSF, UAEM, OXFAM and IQsensato

Program for the meeting: This is a two day technical meeting on issues relating to the design of innovation inducement prizes for low cost rapid point of delivery diagnostic tests (day 1), and for the development of new drugs and vaccines (day 2), for TB and Chagas Disease.

The meeting is designed to cover diagnostics on day one, and drug development on day two. The issues are similar, but there are also a number of differences, as will be evident from the discussion.

Rather than consume time with detailed power point presentations and formal speaking roles, the meeting will mostly be a moderated discussion of a list of topics relating to the design of one or more prizes. Each topic will be briefly introduced by a resource person, and then the group will explore the topic. The plan is to cover every topic at least somewhat, even if the issue cannot be fully resolved at this event. One objective of the meeting is to allow the participants to ask questions, debate and think about the prize design issues in a focused but informal setting. There will be a meeting report outlining the discussions, and reporting consensus where consensus exists, but there will be little pressure on participants to come to conclusions on topics. The primary benefit of the meeting is to introduce the technical topics to the participants, to stimulate discussion and debate, and to build capacity on prize design.

The draft agenda below is accurate in terms of the subjects to be discussed, but not overly specific on how much time each issue will receive.


AGENDA

DAY 1 (January 16, 2009)

Prizes for Development of Low Cost Rapid Point of Care Diagnostic Tests

Friday Chairs, Michelle Childs, MSF and Jamie Love, KEI

 

0900 – 0930 Introduction, welcome and plan of the meeting

0930 – 1000 The Rationale for Prizes for Low Cost, Rapid, Point of Care Diagnostic Tests

1000 – 1100 Overview of Issues in the design of Prizes for Diagnostic Tests

Relationship between push and pull

Medical, technological and economic criteria for prizes

Hard or flexible end points

First Past the Post

Best of

Minimum Requirements

Preferred outcomes

Near misses

Changes in rules

One prize or several prizes?

Single Prize: One winner – Multiple winners

Prizes for Stages or Elements: Milestone prizes – Optional Outcomes

Interim results prizes: Specific Technological Challenges – Periodic “best of”

Follow-on innovation

Incentives for open sharing knowledge and technologies

Open source/Access to knowledge dividend

Evaluation of contestants

Clinical trials to evaluate contestants for grand prize

Evaluation of prizes for stages or elements

Evaluation of Interim results prizes

Evaluation of Open Source/A2K dividend

Licensing of patents, know-how and other intellectual property

Size of the prize(s)

Period of time when offer stands

1100 -1120 Coffee/tea break

1120 – 1230 Design of Diagnostic Prizes (cont.)

The Barbados/Bolivia TB diagnostic prize proposal

The X-Prize work on a TB diagnostic prize

Other approaches

Governance

1230 – 1400 LUNCH

1400 – 1530 Design of diagnostic prizes (cont.)

1530 – 1550 Coffee/tea break

1550 – 1730 Wrap-up and actions steps

1900 Group dinner

DAY 2 (January 17 2009)

Prizes for Development of New Drugs and Vaccines for TB and Chagas Disease

Saturday Morning Chairs, Sophie Bloemen, HAI and Michael Behan

Saturday Afternoon Chairs, James Love, KEI and Sisule Musung, IQsensato

 

0900 – 0930 Rationale for Prizes for Development of New Drugs and Vaccines

0930 – 1030 Overview of Issues in the design of Drug Development and Vaccines Prizes

Relationship between push and pull

Prizes for specific outcomes vs. prizes to reward all products that improve outcomes

The early APC/AMC approach – Focus on standards for qualifying projects

The 2002/Aventis proportional reward approach – Low threshold to qualify for rewards, with fixed prize fund, proportional allocation of funds on the basis on the relative impact of products on health outcomes

Modifications of the proportional reward approach: Fixed credit for new products – Declining credit for additional DALY/QALY

Valuation of products with low expected current utilization:  Inventory and option pricing models /Antibiotics/ Stockpiles for possible threats to public health

Prizes for interim results: Solving discrete problems- Milestone rewards- Valuation of interim results

Evaluation of Outcomes: Evidence – Governance –

Competitive Intermediaries: Selection and funding of intermediaries – Transparency and evidence – Terms of reference

Licensing of patents, know how and other intellectual property

Follow-on innovation

Incentives for open sharing of knowledge and technology

Open source/access to knowledge dividends

Size of prize funds

1030 – 1050 Coffee/tea break

1050 – 1230 Design of Drug Development and Vaccines Prize Funds (cont.)
Specific Proposals

The Barbados/Bolivia Chagas Prize Fund Proposal

The Barbados/Bolivia Licensed Products Prize Fund (LP/pf) for Donors

The Barbados/Bolivia Priority Medicines and Vaccines Prize Fund (PMV/pf)

The FDA Priority Review Voucher

HIF

Advanced Market Commitments for pneumococcal vaccine

Other approaches

1230 – 1400 LUNCH

1400 – 1530 Models for multilateral commitments for sustainable financing

Biomedical R&D Treaty

International Financing Facility (IFF)

UNITAID/PEPFAR/Global Fund

WTO Agreement on Supply of Public Goods

Sui generis funding commitments

1530 – 1545 Coffee/tea break

1545 – 1730 Wrap-up and actions steps

1730 Close